SENATE-BILL 2513: S.2513 - OTC Monograph Drug User Fee Transparency Act

SENATE-BILL 2513 aims to enhance transparency and consumer safety concerning over-the-counter (OTC) drugs by mandating performance reports and public access to negotiation meeting minutes. The legislation addresses major themes of consumer rights, regulatory accountability, and public health by ensuring individuals have access to critical information about OTC medications. Key provisions include the requirement for annual performance reports detailing the FDA's progress on OTC monograph orders and the public availability of negotiation meeting minutes, which collectively aim to empower consumers and improve the regulatory framework. Implementation of these provisions will require the FDA to establish a timeline for reporting and public disclosure, thereby enhancing oversight of the OTC drug supply chain. Potential impacts include increased consumer trust in OTC drug safety, improved access to information, and a strengthened regulatory environment, while also raising constitutional considerations regarding the balance between transparency and confidentiality.

This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.

Analysis generated using AI-powered review of constitutional principles and legal precedents.